Valbiotis SA (ALVAL.PA)
EUR 1.03
(2.07%)
EUR 1.03
(2.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.66 Million EUR | 160.76% |
| 2022 | 767 Thousand EUR | 171.99% |
| 2021 | 282 Thousand EUR | -90.87% |
| 2020 | 3.08 Million EUR | 4072.97% |
| 2019 | 74 Thousand EUR | 123.2% |
| 2018 | -319 Thousand EUR | -383.33% |
| 2017 | -66 Thousand EUR | -110.65% |
| 2016 | 620 Thousand EUR | 2314.29% |
| 2015 | -28 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -925 Thousand EUR | 0.0% |
| 2023 Q4 | -1.57 Million EUR | 0.0% |
| 2023 FY | 2 Million EUR | 160.76% |
| 2023 Q2 | 4.24 Million EUR | 0.0% |
| 2022 Q4 | 150 Thousand EUR | 0.0% |
| 2022 FY | 767 Thousand EUR | 171.99% |
| 2022 Q2 | 635 Thousand EUR | 0.0% |
| 2021 FY | 282 Thousand EUR | -90.87% |
| 2021 Q2 | 148 Thousand EUR | 0.0% |
| 2021 Q4 | 150 Thousand EUR | 0.0% |
| 2020 Q4 | 2.97 Million EUR | 0.0% |
| 2020 FY | 3.08 Million EUR | 4072.97% |
| 2020 Q2 | 121 Thousand EUR | 0.0% |
| 2019 FY | 74 Thousand EUR | 123.2% |
| 2019 Q4 | 45 Thousand EUR | 0.0% |
| 2019 Q2 | 46 Thousand EUR | 0.0% |
| 2018 FY | -319 Thousand EUR | -383.33% |
| 2018 Q4 | 79 Thousand EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2017 Q4 | -37 Thousand EUR | 0.0% |
| 2017 FY | -66 Thousand EUR | -110.65% |
| 2017 Q2 | 40 Thousand EUR | 0.0% |
| 2016 Q1 | 161.5 Thousand EUR | 0.0% |
| 2016 FY | 620 Thousand EUR | 2314.29% |
| 2016 Q4 | 104 Thousand EUR | 0.0% |
| 2016 Q2 | 161.5 Thousand EUR | 0.0% |
| 2015 Q4 | 161.5 Thousand EUR | 0.0% |
| 2015 FY | -28 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -331.715% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 31.834% |
| Adocia SA | 1.38 Million EUR | -92.635% |
| Aelis Farma SA | 12.35 Million EUR | 78.411% |
| Biophytis S.A. | -803 Thousand EUR | 432.254% |
| Advicenne S.A. | 1.42 Million EUR | -87.097% |
| genOway Société anonyme | 20.1 Million EUR | 86.727% |
| IntegraGen SA | 5.01 Million EUR | 46.834% |
| Medesis Pharma S.A. | -2.66 Million EUR | 200.121% |
| Neovacs S.A. | 29.31 Thousand EUR | -9001.453% |
| NFL Biosciences SA | -56.06 Thousand EUR | 4858.847% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -23.925% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 287.981% |
| Sensorion SA | 3.78 Million EUR | 29.564% |
| Theranexus Société Anonyme | -4.63 Million EUR | 157.516% |
| TME Pharma N.V. | -127 Thousand EUR | 2200.787% |
| TheraVet SA | -530.79 Thousand EUR | 602.641% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -110.576% |
| DBV Technologies S.A. | 4.15 Million EUR | 35.859% |
| Genfit S.A. | 28.22 Million EUR | 90.547% |
| GeNeuro SA | -293.8 Thousand EUR | 1008.101% |
| Innate Pharma S.A. | -4.12 Million EUR | 164.742% |
| Inventiva S.A. | 17.5 Million EUR | 84.754% |
| MaaT Pharma SA | 1.65 Million EUR | -61.208% |
| MedinCell S.A. | 9.28 Million EUR | 71.275% |
| Nanobiotix S.A. | 36.2 Million EUR | 92.631% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -19.802% |
| Poxel S.A. | 1000.00 EUR | -266700.0% |
| GenSight Biologics S.A. | 3 Million EUR | 11.067% |
| Transgene SA | -28.4 Million EUR | 109.393% |
| Valneva SE | 52.83 Million EUR | 94.951% |